Last update 16 May 2025

QLP-31907

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
PSB 202, PSB-202, PSB202
+ [3]
Action
modulators
Mechanism
CD20 modulators(B-lymphocyte antigen CD20 modulators), CD37 modulators(Leukocyte antigen CD37 modulators)
Active Indication
Originator Organization
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-Cell Malignant NeoplasmPhase 1
United States
23 Feb 2022
B-Cell Malignant NeoplasmPhase 1
China
23 Feb 2022
B-Cell Malignant NeoplasmPhase 1
Australia
23 Feb 2022
B-cell lymphoma refractoryPhase 1
United States
15 Nov 2021
B-cell lymphoma refractoryPhase 1
China
15 Nov 2021
B-cell lymphoma refractoryPhase 1
Australia
15 Nov 2021
Chronic Lymphocytic LeukemiaPhase 1
United States
15 Nov 2021
Chronic Lymphocytic LeukemiaPhase 1
China
15 Nov 2021
Chronic Lymphocytic LeukemiaPhase 1
Australia
15 Nov 2021
Follicular LymphomaPhase 1
United States
15 Nov 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
bquorxznsp(hbihraphqb) = wdolyswxho wrypxmgzau (nevaaffkin )
-
15 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free